Your browser is no longer supported. Please, upgrade your browser.
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.88 Insider Own0.70% Shs Outstand158.10M Perf Week0.51%
Market Cap3.15B Forward P/E46.11 EPS next Y0.43 Insider Trans-27.13% Shs Float157.21M Perf Month17.27%
Income-138.90M PEG- EPS next Q-0.02 Inst Own96.66% Short Float7.28% Perf Quarter27.61%
Sales1.19B P/S2.64 EPS this Y-39.40% Inst Trans4.00% Short Ratio7.26 Perf Half Y2.50%
Book/sh6.72 P/B2.93 EPS next Y2250.00% ROA-7.80% Target Price19.09 Perf Year-14.17%
Cash/sh3.10 P/C6.36 EPS next 5Y24.00% ROE-12.90% 52W Range11.98 - 25.35 Perf YTD-3.48%
Dividend- P/FCF- EPS past 5Y-43.30% ROI-12.80% 52W High-22.33% Beta1.48
Dividend %- Quick Ratio2.40 Sales past 5Y13.60% Gross Margin84.70% 52W Low64.36% ATR0.80
Employees2235 Current Ratio2.70 Sales Q/Q10.40% Oper. Margin-11.50% RSI (14)62.30 Volatility3.70% 4.90%
OptionableYes Debt/Eq0.26 EPS Q/Q60.30% Profit Margin-11.60% Rel Volume0.69 Prev Close20.04
ShortableYes LT Debt/Eq0.26 EarningsApr 29 BMO Payout- Avg Volume1.58M Price19.69
Recom2.90 SMA205.75% SMA5016.17% SMA2008.77% Volume1,084,617 Change-1.75%
Feb-14-20Reiterated H.C. Wainwright Neutral $26 → $25
Feb-14-20Downgrade JP Morgan Overweight → Neutral $21
Feb-14-20Downgrade BofA/Merrill Buy → Neutral $31 → $20
Feb-06-20Initiated Mizuho Neutral
Jan-31-20Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19Upgrade Morgan Stanley Underweight → Equal-Weight $30 → $20
Jul-15-19Upgrade Goldman Sell → Neutral
May-31-19Initiated H.C. Wainwright Neutral
May-01-19Downgrade Citigroup Buy → Neutral
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Jun-30-20 09:36AM  
Jun-29-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 09:01AM  
Jun-19-20 06:04PM  
Jun-16-20 07:28AM  
Jun-12-20 09:11AM  
Jun-08-20 09:04AM  
Jun-04-20 04:00PM  
May-29-20 11:31AM  
May-27-20 07:00AM  
May-20-20 07:00AM  
May-14-20 07:00AM  
May-11-20 07:00AM  
May-06-20 04:00PM  
May-01-20 09:45AM  
Apr-30-20 11:12AM  
Apr-29-20 03:00PM  
07:47AM  
07:00AM  
Apr-28-20 11:58AM  
11:40AM  
Apr-22-20 04:00PM  
08:49AM  
07:00AM  
Apr-16-20 12:31PM  
Apr-04-20 10:02AM  
Mar-29-20 10:25PM  
Mar-26-20 02:53PM  
Mar-14-20 11:30AM  
Mar-04-20 07:00AM  
Feb-28-20 05:32AM  
Feb-24-20 04:00PM  
02:08PM  
Feb-19-20 04:01PM  
Feb-18-20 11:18PM  
Feb-14-20 10:49AM  
10:46AM  
Feb-13-20 09:32AM  
09:05AM  
08:05AM  
07:00AM  
05:00AM  
Feb-10-20 09:28AM  
Feb-06-20 04:00PM  
12:30PM  
Jan-29-20 09:54AM  
Jan-28-20 07:00AM  
Jan-16-20 05:50PM  
Jan-13-20 09:40AM  
05:11AM  
Jan-10-20 05:50PM  
Jan-08-20 04:00PM  
Jan-06-20 11:40AM  
Dec-30-19 10:23AM  
09:44AM  
Dec-26-19 07:22AM  
Dec-24-19 01:12PM  
Dec-20-19 05:50PM  
12:00PM  
09:28AM  
08:27AM  
08:13AM  
Dec-19-19 08:59AM  
Dec-18-19 08:50AM  
07:59AM  
Dec-17-19 10:25AM  
09:59AM  
Dec-16-19 03:55PM  
09:46AM  
08:06AM  
08:05AM  
Dec-13-19 08:33AM  
Dec-12-19 09:36AM  
09:10AM  
Dec-11-19 12:12PM  
12:03PM  
11:25AM  
Dec-10-19 09:26AM  
Dec-09-19 04:31PM  
04:03PM  
Dec-08-19 07:52AM  
Dec-06-19 09:26AM  
09:17AM  
Dec-05-19 10:02AM  
09:07AM  
Dec-04-19 10:10AM  
09:29AM  
Dec-03-19 03:18PM  
09:16AM  
08:29AM  
Nov-29-19 09:26AM  
09:13AM  
Nov-27-19 08:52AM  
Nov-26-19 08:36AM  
08:24AM  
Nov-25-19 09:18AM  
07:00AM  
Nov-22-19 09:45AM  
09:31AM  
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 07Option Exercise0.001,250015,201Jun 08 04:21 PM
Nichols Christian ToddSVP, Chief Commercial OfficerJun 05Option Exercise0.003,50003,500Jun 08 04:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 14Option Exercise11.7475,000880,500834,094May 14 05:00 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 14Option Exercise11.7421,983258,08091,828May 14 04:58 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 14Sale15.0075,0001,125,233759,094May 14 05:00 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 13Option Exercise11.746,25073,37544,831May 14 04:55 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 13Sale15.396,25096,19338,581May 14 04:55 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 12Option Exercise11.7418,000211,320219,822May 14 04:54 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 12Sale15.7518,000283,469201,822May 14 04:54 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 07Option Exercise11.7450,000587,000809,094May 07 04:26 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 07Sale14.6350,000731,265759,094May 07 04:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 05Option Exercise11.7425,000293,500226,822May 07 04:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 05Sale14.0625,000351,425201,822May 07 04:25 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 02Option Exercise11.7450,000587,000809,094Apr 03 04:22 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 02Sale13.7950,000689,500759,094Apr 03 04:22 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 26Option Exercise11.7475,000880,500834,094Mar 26 04:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 26Sale14.3675,0001,077,225759,094Mar 26 04:38 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 24Option Exercise11.7425,000293,500226,822Mar 26 04:36 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 24Sale13.9125,000347,718201,822Mar 26 04:36 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 19Option Exercise11.7475,000880,500834,094Mar 19 04:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 19Sale14.4775,0001,085,428759,094Mar 19 04:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 17Option Exercise11.7425,000293,500226,822Mar 19 04:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 17Sale13.5425,000338,506201,822Mar 19 04:10 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 02Option Exercise11.743,00035,22061,934Mar 03 04:31 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000766,864Mar 03 04:36 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000201,822Mar 03 04:33 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250059,596Mar 03 04:31 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500071,168Mar 03 04:27 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250039,243Mar 03 04:23 PM
Wysenski NancyDirectorFeb 24Buy19.656,940136,37111,242Feb 25 05:15 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 21Option Exercise0.0032,4000763,750Feb 24 04:15 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 21Option Exercise0.005,8250197,322Feb 24 04:14 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 21Option Exercise0.006,875015,955Feb 24 04:13 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 21Option Exercise0.006,875059,362Feb 24 04:12 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 21Option Exercise0.005,825068,380Feb 24 04:11 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 21Option Exercise0.004,800038,384Feb 24 04:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500735,236Feb 18 04:12 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000191,497Feb 18 04:11 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500053,253Feb 18 04:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,000063,459Feb 18 04:07 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500034,452Feb 18 04:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 16Option Exercise0.0018,1250734,558Feb 18 04:12 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 16Option Exercise0.003,375010,252Feb 18 04:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 16Option Exercise0.003,3750188,497Feb 18 04:11 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 16Option Exercise0.003,375051,925Feb 18 04:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 16Option Exercise0.003,375061,631Feb 18 04:07 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 16Option Exercise0.002,375032,777Feb 18 04:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Option Exercise9.21100,000921,000816,433Nov 15 04:08 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Sale19.50100,0001,950,000716,433Nov 15 04:08 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Option Exercise9.2120,000184,200205,122Nov 15 04:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Sale19.7020,000394,056185,122Nov 15 04:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Option Exercise9.2130,205278,188746,638Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Sale19.7330,205595,827716,433Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Option Exercise9.2169,795642,812786,228Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Sale19.8169,7951,382,618716,433Nov 08 04:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Option Exercise9.2120,000184,200205,122Nov 08 04:04 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Sale19.7620,000395,116185,122Nov 08 04:04 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 19Option Exercise9.21100,000921,000816,433Sep 23 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 19Sale21.54100,0002,153,550716,433Sep 23 06:16 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSSep 13Option Exercise11.7420,000234,80058,256Sep 17 07:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Option Exercise9.21100,000921,000816,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Sale22.68100,0002,268,220716,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Option Exercise9.21100,000921,000816,433Sep 06 05:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Sale20.18100,0002,017,830716,433Sep 06 05:01 PM